Privo Technologies Acquires Medico Pharma In Strategic Move
23 Jan 2026 //
PR NEWSWIRE
Privo Begins Dosing PRV-131 in Arm 3 of CLN-004 Oral Cancer Trial
10 Dec 2025 //
PR NEWSWIRE
PRV111, Meets Primary Efficacy Endpoint In Phase 2/3 Trial
17 Nov 2025 //
PR NEWSWIRE
Privo Technologies Wraps Phase 2 Run-In In PRV111 Oral Cancer
14 Oct 2025 //
PR NEWSWIRE
Privo Technologies Launches BeneVet Oncology: Advancing Comp
24 Mar 2025 //
PR NEWSWIRE
Privo Appoints Dr. Albert Collinson as Independent Non-Executive Director
09 Nov 2023 //
PR NEWSWIRE
Privo Technologies Receives U.S. FDA Orphan Drug Designation
12 Aug 2022 //
PRNEWSWIRE

Market Place
Sourcing Support